- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 14.04. | Novo teams with OpenAI; Ideaya gets muted response to eye drug data | ||
| 14.04. | Lilly boosts ADC portfolio with CrossBridge Bio deal | ||
| 13.04. | Spyre drug for inflammatory bowel disease shows promise in early study | ||
| 13.04. | Allogene data suggest 'off-the-shelf' CAR-T could delay relapse in lymphoma | ||
| 13.04. | Revolution pancreatic cancer drug nearly doubles survival in key trial | ||
| 13.04. | Connected medical devices: Smarter care starts here | ||
| 13.04. | Rethinking dermatology trial design for late-stage success | ||
| 10.04. | FDA again spurns Replimune melanoma drug | ||
| 10.04. | Oricell closes a 'pre-IPO' megaround to aim CAR-T at solid tumors | ||
| 10.04. | RFK Jr. rewrites ACIP rules; Gilead, Roche dig into protein degraders | ||
| 10.04. | Women have awaited a revolution in menopause. It hasn't arrived. | ||
| 09.04. | Invivyd reveals plans to test an antibody drug against measles | ||
| 09.04. | Chasing a tough-to-treat lung disease, Avalyn plans an IPO | ||
| 09.04. | Lilly launches GLP-1 pill, kicking off showdown with Novo Nordisk | ||
| 08.04. | Sidewinder secures $137M to advance 'precision' ADCs | ||
| 08.04. | With 3 quick buyouts, Gilead leans into its latest transformation | ||
| 08.04. | Activist investor revives campaign to overhaul Novavax board | ||
| 08.04. | Novo underprices Lilly with higher-dose Wegovy; Insmed absorbs 'expected' study failure | ||
| 08.04. | Jeito Capital, prominent biotech investor, raises $1.2B for next fund | ||
| 07.04. | Terns rebuffed a higher bid before selling to Merck | ||
| 07.04. | Gilead continues M&A surge with $3.1B deal for ADC specialist Tubulis | ||
| 07.04. | Sanofi immune drug hopeful posts mixed results in mid-stage tests | ||
| 06.04. | Hims & Hers says limited data stolen in social engineering attack | ||
| 06.04. | Under-the-skin Tepezza comparable to infused version in key study, Amgen says | ||
| 06.04. | FDA floats new clinical trial reforms; Takeda punts Denali brain drug |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.